Pfizer (PFE)
(Delayed Data from NYSE)
$28.01 USD
-0.17 (-0.60%)
Updated May 10, 2024 04:00 PM ET
After-Market: $28.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PFE 28.01 -0.17(-0.60%)
Will PFE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PFE
Top Stock Reports for Amazon.com, Visa & Pfizer
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Here's Why Pfizer (PFE) is a Strong Momentum Stock
Other News for PFE
Organon Graduates From Spinoff Skepticism, With A Yield Above 5%
Novavax hits 52-week high as Sanofi deal brings upgrades (update)
Novavax hits a 52-week high as Sanofi deal prompts J.P. Morgan upgrade
Top Stock Reports For Amazon.com, Visa & Pfizer
Morning Brew: Stock Futures Rise Ahead of Key Economic Reports